The current store does not ship to your location.
Biologics License Application (BLA) marks a significant milestone in expanding access to anemia treatments. As a biosimilar to US-licensed Epogen, Retacrit (epoetin alfa-epbx) provides a cost-effective alternative for treating anemia caused by chronic kidney disease, chemotherapy, or zidovudine in HIV-infected patients. Key highlights from the FDA review:
Increased competition in the biologics space continues to drive down healthcare costs while maintaining high standards for patient safety. 125545
: Intravenous or subcutaneous, with IV recommended for hemodialysis patients. 125545
: A popular Explorer Forum thread (ID 125545) regarding manual transfer case conversions. 125545
#Biosimilars #FDA #Hematology #PharmaNews #HealthcareInnovation Clinical Spotlight: Retacrit (epoetin alfa-epbx)
: Supported for both adult and pediatric patients.